Developer docs
API playgroundTry for free, no card

Search company profiles

QuantuMDx Group

Full company profile

uuid0002jhi

Namestring
QuantuMDx Group
Legal namestring
QuantuMDx Group Limited
Websiteurl
quantumdx.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

QuantuMDx Group Limited is a privately held UK medical device company headquartered in Newcastle upon Tyne that develops portable molecular diagnostic platforms for use at the point of care. Founded in 2008, the company builds the Q-POC system, a battery-operated, sample-to-answer multiplex PCR device that compresses a molecular diagnostic laboratory into a single portable instrument and delivers results in approximately 30 minutes for the SARS-CoV-2 assay and 35 minutes for the multiplex respiratory panel (SARS-CoV-2, Flu A/B, RSV). The platform uses lyophilised on-board reagents in sealed single-use cassettes and connects to Laboratory Information Systems via HL7 v3 CDA over Wi-Fi or ethernet (software v3.2). The company is also developing a Capture-XT microfluidic dielectrophoresis platform for sample preparation and cell concentration, and a multiplex STI Plus AMR assay targeting Chlamydia, Gonorrhoeae, Trichomonas, and Mycoplasma with antimicrobial resistance mutation detection.

The company's revenue model combines hardware sales of the Q-POC instrument with recurring consumable revenue from single-use test cassettes, supplemented by licensing and royalty payments from distribution partners. QuantuMDx sells primarily through exclusive channel partners: A.Menarini Diagnostics holds five-year exclusive UK and France rights, and Sansure Biotech holds exclusive China rights under a cooperation agreement that also covers R&D and manufacturing optimization. Direct channels include the UK government via the Public Health England National Microbiology Framework and selective enterprise deployments such as Cignpost Diagnostics for film and TV industry workplace testing. End customers span NHS hospital systems, point-of-care clinics and pharmacies, care homes, sexual health services, and resource-limited settings.

Since January 2020 the company has raised approximately £37 million, including a £16 million UK government grant (March 2020), an £11 million convertible loan with Future Fund participation (March 2021), and a £15 million equity investment from Hong Kong-based Vita Spring IVD Fund (November 2021). It holds CE-IVD marking under IVDR, CTDA approval from the UK Health Security Agency for its SARS-CoV-2 assays, ISO 13485 accreditation, and is included in both lots of the PHE National Microbiology Framework. The company employs 51-100 people and remains in early commercialization with no disclosed revenue.

Short descriptiontext

QuantuMDx Group is a UK medical device company that develops the Q-POC portable sample-to-answer multiplex PCR diagnostic platform and consumable assays, serving hospitals, clinics, pharmacies, and enterprises through distribution partners including Menarini and Sansure Biotech.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewcastle Upon Tyne, United Kingdom
HQ citystring
Newcastle Upon Tyne
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics devices, point-of-care PCR testing, infectious disease assays, antimicrobial resistance testing, portable diagnostic platforms
Industry3 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Point-of-Care Molecular Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Q-POC Hardware Device Sales
TypeHardware Sales
Description

Sale of the Q-POC portable PCR analyzer instrument to healthcare facilities, clinics, and enterprises.

quantumdx.com
2Assay/Reagent Consumables
TypeHardware Sales
Description

Recurring sales of single-use test cassettes (SARS-CoV-2, Respiratory Panel, STI assays) for the Q-POC platform.

quantumdx.com
3Licensing and Royalty Payments
TypeLicensing Royalties
Description

QuantuMDx receives licensing and royalty payments from Sansure for exclusive rights to Q-POC in China.

quantumdx.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1No tiered pricing structure publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; direct inquiries and sales partner quotes required for Q-POC device and assay purchases.

quantumdx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Q-POC™
Description

A rapid, simple to use, portable, sample-to-answer multiplex PCR device designed for use in hospitals, clinics, pharmacies, and workplaces providing accurate PCR results at the point of need. CE-IVD marked and CTDA approved for SARS-CoV-2 testing.

quantumdx.com
+1 more record
Core offering1 text field

QuantuMDx designs, develops, and manufactures the Q-POC portable PCR diagnostic instrument and a menu of single-use test cassettes (assays) for rapid molecular detection of infectious diseases at the point of care. Core products include the Q-POC analyzer, the SARS-CoV-2 detection assay, the SARS-CoV-2/Flu A/B/RSV respiratory panel assay, an STI Plus AMR assay in development, and the Capture-XT microfluidic sample preparation platform in development. Revenue is generated through instrument sales and recurring consumable cassette sales, supplemented by licensing/royalty arrangements with regional partners such as Sansure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 96.9% sensitivity and 98.3% specificity for SARS-CoV-2 detection
+3 more records
Product overview1 text field

QuantuMDx delivers next-generation molecular diagnostics through its Q-POC™ platform and expanding range of assays. The Q-POC™ is a rapid, portable, sample-to-answer multiplex PCR device that compresses an entire molecular diagnostic laboratory into a single device, delivering results in approximately 30 minutes at the point of need. The system comprises a portable analyzer instrument, single-use test cassettes, and sample collection kits. The assay portfolio includes the SARS-CoV-2 detection assay, the SARS-CoV-2/Flu A/B/RSV respiratory panel, and the STI Plus AMR assay (in development). Additionally, Capture-XT is a novel microfluidic sample preparation and cell concentration technology in development using dielectrophoresis.

Product and service4 records
1Q-POC Point-of-Care PCR System
CategoryDiagnostic Instrument Platform
Description

A rapid, portable, battery-operated, sample-to-answer multiplex PCR diagnostic device that delivers lab-quality molecular diagnostic results in approximately 30 minutes at the point of need. Designed for use by frontline healthcare professionals in hospitals, clinics, pharmacies, and workplaces.

2Q-POC SARS-CoV-2, Flu A/B & RSV Assay
CategoryDiagnostic Assay / Consumable
Description

A multiplex respiratory panel assay that detects SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) on the Q-POC platform, enabling differential diagnosis and rapid triage in approximately 35 minutes at the point of care.

3Q-POC STI Plus AMR Assay
CategoryDiagnostic Assay / Consumable (in development)
Description

A multiplex assay in development designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, with AMR mutation detection for Neisseria gonorrhoeae and Mycoplasma genitalium to guide targeted antibiotic treatment.

4Capture-XT Sample Preparation Platform
CategorySample Preparation Platform (in development)
Description

A novel microfluidic lab-on-a-chip sample cleanup and cell concentration technology using dielectrophoresis (DEP) to selectively capture and concentrate target particles. Currently in development; preserves cell viability for downstream analysis including culture and molecular testing.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-11-02
Description

Part of Menarini Pharmaceutical Group (founded 1886, present in 140 countries). Five-year exclusive distribution agreement covering UK and France for Q-POC platform and assays, with potential to expand to other markets.

2Sansure Biotech Inc.
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-09-06
Description

In-vitro diagnostic solution provider based in Changsha, China (founded 2008). Global R&D, manufacturing and commercial partnership granting Sansure exclusive rights to Q-POC in China. QuantuMDx receives licensing and royalty payments. Also enables component sourcing and manufacturing optimization.

quantumdx.com
3Cignpost Diagnostics
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-08-16
Description

Leading provider of COVID-19 workplace testing to UK film and TV industry. Installed Q-POC systems for rapid, onsite PCR testing for cast and crew.

quantumdx.com
Strategic tierSupportingTypeTechnology or Integration
Description

UK-based manufacturing partner for Q-POC instrument production.

Strategic tierSupportingTypeTechnology or Integration
Description

Singapore-based manufacturing partner for Q-POC production.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical evaluation of Q-POC SARS-CoV-2 assay through DART Study. Published performance data showing 96.9% sensitivity and 98.3% specificity.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cepheid's GeneXpert system is the dominant rapid PCR platform in hospitals and reference labs globally. It is the most direct benchmark for Q-POC's sample-to-answer molecular diagnostic value proposition, with a much larger installed base and assay menu.

2Abbott (ID NOW)
TypeDirect peer
Description

Abbott's ID NOW is a rapid, portable molecular isothermal device used at the point of care. It competes head-to-head with Q-POC in decentralised settings such as urgent care, clinics, and pharmacies for rapid infectious disease diagnostics.

TypeDirect peer
Description

Visby Medical produces a single-use, palm-sized PCR device for rapid infectious disease testing (e.g., STI, respiratory). It targets the same decentralised, rapid-PCR point-of-care niche as Q-POC with a more disposable form factor.

TypeEmerging player
Description

Binx Health focuses on rapid molecular diagnostics for sexual health (chlamydia/gonorrhoeae at the point of care), with the io system. It is an emerging player addressing the same STI testing market that QuantuMDx's STI Plus AMR assay targets.

TypeDirect peer
Description

QIAstat-Dx is a multiplex sample-to-answer PCR system with syndromic panels, offering comparable time-to-result and ease-of-use positioning to Q-POC in hospital and clinic settings.

6Cue Health
TypeDirect peer
Description

Cue Health offers a connected, cartridge-based rapid molecular diagnostic platform for at-home and point-of-care use. It is a direct competitor in portable PCR/molecular diagnostics aimed at consumer and clinical decentralised testing.

TypeDirect peer
Description

BioFire FilmArray panels deliver multiplex syndromic PCR testing (respiratory, GI, meningitis/encephalitis) in a compact instrument. It overlaps with Q-POC's respiratory and STI multiplex ambitions and competes for hospital POC placements.

TypeDirect peer
Description

The Accula rapid PCR platform targets point-of-care infectious disease testing (e.g., SARS-CoV-2, Flu A/B, RSV, Strep A). It competes directly with Q-POC in clinic and pharmacy-based POC PCR workflows.

TypeBroad incumbent
Description

Hologic's Panther and Panther Fusion systems are high-throughput molecular diagnostic platforms with a broad women's health and infectious disease menu. As a larger incumbent, Hologic competes in the same IVD molecular diagnostics category but focuses on central-lab throughput rather than Q-POC's portability.

TypeEmerging player
Description

Genedrive is a UK-based molecular diagnostics company developing rapid, near-patient PCR assays (e.g., HCV, neonatal hearing loss, infectious disease). It is a comparable emerging player in portable, point-of-need molecular diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QuantuMDx Group

Point-of-Care Molecular Diagnosticsquantumdx.com

QuantuMDx Group is a UK medical device company that develops the Q-POC portable sample-to-answer multiplex PCR diagnostic platform and consumable assays, serving hospitals, clinics, pharmacies, and enterprises through distribution partners including Menarini and Sansure Biotech.

What QuantuMDx Group does

QuantuMDx Group Limited is a privately held UK medical device company headquartered in Newcastle upon Tyne that develops portable molecular diagnostic platforms for use at the point of care. Founded in 2008, the company builds the Q-POC system, a battery-operated, sample-to-answer multiplex PCR device that compresses a molecular diagnostic laboratory into a single portable instrument and delivers results in approximately 30 minutes for the SARS-CoV-2 assay and 35 minutes for the multiplex respiratory panel (SARS-CoV-2, Flu A/B, RSV). The platform uses lyophilised on-board reagents in sealed single-use cassettes and connects to Laboratory Information Systems via HL7 v3 CDA over Wi-Fi or ethernet (software v3.2). The company is also developing a Capture-XT microfluidic dielectrophoresis platform for sample preparation and cell concentration, and a multiplex STI Plus AMR assay targeting Chlamydia, Gonorrhoeae, Trichomonas, and Mycoplasma with antimicrobial resistance mutation detection.

The company's revenue model combines hardware sales of the Q-POC instrument with recurring consumable revenue from single-use test cassettes, supplemented by licensing and royalty payments from distribution partners. QuantuMDx sells primarily through exclusive channel partners: A.Menarini Diagnostics holds five-year exclusive UK and France rights, and Sansure Biotech holds exclusive China rights under a cooperation agreement that also covers R&D and manufacturing optimization. Direct channels include the UK government via the Public Health England National Microbiology Framework and selective enterprise deployments such as Cignpost Diagnostics for film and TV industry workplace testing. End customers span NHS hospital systems, point-of-care clinics and pharmacies, care homes, sexual health services, and resource-limited settings.

Since January 2020 the company has raised approximately £37 million, including a £16 million UK government grant (March 2020), an £11 million convertible loan with Future Fund participation (March 2021), and a £15 million equity investment from Hong Kong-based Vita Spring IVD Fund (November 2021). It holds CE-IVD marking under IVDR, CTDA approval from the UK Health Security Agency for its SARS-CoV-2 assays, ISO 13485 accreditation, and is included in both lots of the PHE National Microbiology Framework. The company employs 51-100 people and remains in early commercialization with no disclosed revenue.

QuantuMDx Group firmographics

Firmographics
Name
QuantuMDx Group
Legal name
QuantuMDx Group Limited
Website
https://quantumdx.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
QuantuMDx Group is a UK medical device company that develops the Q-POC portable sample-to-answer multiplex PCR diagnostic platform and consumable assays, serving hospitals, clinics, pharmacies, and enterprises through distribution partners including Menarini and Sansure Biotech.
Ownership category
akta.pro rank

QuantuMDx Group industry classification

Industry
Product category
Point-of-Care Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Molecular diagnostics devices
  • Point-of-care PCR testing
  • Infectious disease assays
  • Antimicrobial resistance testing
  • Portable diagnostic platforms

Where QuantuMDx Group is headquartered

Location

Headquarters

HQ city
Newcastle Upon Tyne
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

QuantuMDx Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Q-POC Hardware Device Sales: Sale of the Q-POC portable PCR analyzer instrument to healthcare facilities, clinics, and enterprises.
  2. Assay/Reagent Consumables: Recurring sales of single-use test cassettes (SARS-CoV-2, Respiratory Panel, STI assays) for the Q-POC platform.
  3. Licensing and Royalty Payments: QuantuMDx receives licensing and royalty payments from Sansure for exclusive rights to Q-POC in China.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNo tiered pricing structure publicly disclosed

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

QuantuMDx Group product offering

Product offering

Core offering

QuantuMDx designs, develops, and manufactures the Q-POC portable PCR diagnostic instrument and a menu of single-use test cassettes (assays) for rapid molecular detection of infectious diseases at the point of care. Core products include the Q-POC analyzer, the SARS-CoV-2 detection assay, the SARS-CoV-2/Flu A/B/RSV respiratory panel assay, an STI Plus AMR assay in development, and the Capture-XT microfluidic sample preparation platform in development. Revenue is generated through instrument sales and recurring consumable cassette sales, supplemented by licensing/royalty arrangements with regional partners such as Sansure.

Product overview

QuantuMDx delivers next-generation molecular diagnostics through its Q-POC™ platform and expanding range of assays. The Q-POC™ is a rapid, portable, sample-to-answer multiplex PCR device that compresses an entire molecular diagnostic laboratory into a single device, delivering results in approximately 30 minutes at the point of need. The system comprises a portable analyzer instrument, single-use test cassettes, and sample collection kits. The assay portfolio includes the SARS-CoV-2 detection assay, the SARS-CoV-2/Flu A/B/RSV respiratory panel, and the STI Plus AMR assay (in development). Additionally, Capture-XT is a novel microfluidic sample preparation and cell concentration technology in development using dielectrophoresis.

Differentiator

Problem solved

Functional benefit

Brands

  • Q-POC™: A rapid, simple to use, portable, sample-to-answer multiplex PCR device designed for use in hospitals, clinics, pharmacies, and workplaces providing accurate PCR results at the point of need. CE-IVD marked and CTDA approved for SARS-CoV-2 testing.
  • CAPTURE-XT

Products and services

  • Q-POC Point-of-Care PCR System A rapid, portable, battery-operated, sample-to-answer multiplex PCR diagnostic device that delivers lab-quality molecular diagnostic results in approximately 30 minutes at the point of need. Designed for use by frontline healthcare professionals in hospitals, clinics, pharmacies, and workplaces.
  • Q-POC SARS-CoV-2, Flu A/B & RSV Assay A multiplex respiratory panel assay that detects SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) on the Q-POC platform, enabling differential diagnosis and rapid triage in approximately 35 minutes at the point of care.
  • Q-POC STI Plus AMR Assay A multiplex assay in development designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, with AMR mutation detection for Neisseria gonorrhoeae and Mycoplasma genitalium to guide targeted antibiotic treatment.
  • Capture-XT Sample Preparation Platform A novel microfluidic lab-on-a-chip sample cleanup and cell concentration technology using dielectrophoresis (DEP) to selectively capture and concentrate target particles. Currently in development; preserves cell viability for downstream analysis including culture and molecular testing.

Quantifiable outcome

  • 96.9% sensitivity and 98.3% specificity for SARS-CoV-2 detection
  • +3 more outcomes

Companies that use QuantuMDx Group

Customer profile

Named customers4 records

Segments6 records

Ideal customer profiles5 records

QuantuMDx Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

QuantuMDx Group partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, flagship, secondary and supporting.

  • A.Menarini Diagnostics S.r.I.coreChannel Partner/ Reseller/ Distributor · 2 November 2022Part of Menarini Pharmaceutical Group (founded 1886, present in 140 countries). Five-year exclusive distribution agreement covering UK and France for Q-POC platform and assays, with potential to expand to other markets.
  • Sansure Biotech Inc.flagshipStrategic or Co-development Partner · 6 September 2022In-vitro diagnostic solution provider based in Changsha, China (founded 2008). Global R&D, manufacturing and commercial partnership granting Sansure exclusive rights to Q-POC in China. QuantuMDx receives licensing and royalty payments. Also enables component sourcing and manufacturing optimization.
  • Cignpost DiagnosticssecondaryChannel Partner/ Reseller/ Distributor · 16 August 2021Leading provider of COVID-19 workplace testing to UK film and TV industry. Installed Q-POC systems for rapid, onsite PCR testing for cast and crew.
  • Cogent TechnologysupportingTechnology or IntegrationUK-based manufacturing partner for Q-POC instrument production.
  • UnivacsupportingTechnology or IntegrationSingapore-based manufacturing partner for Q-POC production.
  • St George's, University of LondonsupportingStrategic or Co-development PartnerClinical evaluation of Q-POC SARS-CoV-2 assay through DART Study. Published performance data showing 96.9% sensitivity and 98.3% specificity.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

QuantuMDx Group competitors and assessment

Company assessment

Direct peers

  • Cepheid (Danaher): Cepheid's GeneXpert system is the dominant rapid PCR platform in hospitals and reference labs globally. It is the most direct benchmark for Q-POC's sample-to-answer molecular diagnostic value proposition, with a much larger installed base and assay menu.
  • Abbott (ID NOW): Abbott's ID NOW is a rapid, portable molecular isothermal device used at the point of care. It competes head-to-head with Q-POC in decentralised settings such as urgent care, clinics, and pharmacies for rapid infectious disease diagnostics.
  • Visby Medical: Visby Medical produces a single-use, palm-sized PCR device for rapid infectious disease testing (e.g., STI, respiratory). It targets the same decentralised, rapid-PCR point-of-care niche as Q-POC with a more disposable form factor.
  • QIAGEN (QIAstat-Dx): QIAstat-Dx is a multiplex sample-to-answer PCR system with syndromic panels, offering comparable time-to-result and ease-of-use positioning to Q-POC in hospital and clinic settings.
  • Cue Health: Cue Health offers a connected, cartridge-based rapid molecular diagnostic platform for at-home and point-of-care use. It is a direct competitor in portable PCR/molecular diagnostics aimed at consumer and clinical decentralised testing.
  • bioMérieux (BioFire FilmArray): BioFire FilmArray panels deliver multiplex syndromic PCR testing (respiratory, GI, meningitis/encephalitis) in a compact instrument. It overlaps with Q-POC's respiratory and STI multiplex ambitions and competes for hospital POC placements.
  • Mesa Labs (Accula, now part of Thermo Fisher): The Accula rapid PCR platform targets point-of-care infectious disease testing (e.g., SARS-CoV-2, Flu A/B, RSV, Strep A). It competes directly with Q-POC in clinic and pharmacy-based POC PCR workflows.

Emerging players

  • Binx Health: Binx Health focuses on rapid molecular diagnostics for sexual health (chlamydia/gonorrhoeae at the point of care), with the io system. It is an emerging player addressing the same STI testing market that QuantuMDx's STI Plus AMR assay targets.
  • Genedrive: Genedrive is a UK-based molecular diagnostics company developing rapid, near-patient PCR assays (e.g., HCV, neonatal hearing loss, infectious disease). It is a comparable emerging player in portable, point-of-need molecular diagnostics.

Broad incumbents

  • Hologic (Panther / Panther Fusion): Hologic's Panther and Panther Fusion systems are high-throughput molecular diagnostic platforms with a broad women's health and infectious disease menu. As a larger incumbent, Hologic competes in the same IVD molecular diagnostics category but focuses on central-lab throughput rather than Q-POC's portability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

QuantuMDx Group social profiles

Digital presence

QuantuMDx Group compliance and trust

Trust signal

Compliance5 records

QuantuMDx Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QuantuMDx Group leadership team

Management profile

Number of profiles

Profiles10 records

QuantuMDx Group funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QuantuMDx Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QuantuMDx Group

What does QuantuMDx Group do?

QuantuMDx designs, develops, and manufactures the Q-POC portable PCR diagnostic instrument and a menu of single-use test cassettes (assays) for rapid molecular detection of infectious diseases at the point of care. Core products include the Q-POC analyzer, the SARS-CoV-2 detection assay, the SARS-CoV-2/Flu A/B/RSV respiratory panel assay, an STI Plus AMR assay in development, and the Capture-XT microfluidic sample preparation platform in development. Revenue is generated through instrument sales and recurring consumable cassette sales, supplemented by licensing/royalty arrangements with regional partners such as Sansure.

Is QuantuMDx Group a public or private company?

QuantuMDx Group is a private company. It is classified as venture growth investor backed and is currently operating.

When was QuantuMDx Group founded?

QuantuMDx Group was founded in 2008. It employs 11 to 50 people.

Where is QuantuMDx Group based?

QuantuMDx Group is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.

How does QuantuMDx Group make money?

Three revenue lines are on record. Q-POC Hardware Device Sales are the primary driver. The others are assay/Reagent Consumables and licensing and Royalty Payments.

Who are QuantuMDx Group's main competitors?

Direct peers on record are Cepheid (Danaher), Abbott (ID NOW), Visby Medical, QIAGEN (QIAstat-Dx), Cue Health, bioMérieux (BioFire FilmArray) and Mesa Labs (Accula, now part of Thermo Fisher). Emerging players are Binx Health and Genedrive. Hologic (Panther / Panther Fusion) is listed as a broad incumbent.

Does QuantuMDx Group have an API?

No public API is recorded for QuantuMDx Group.

What industry is QuantuMDx Group in?

QuantuMDx Group's product category is Point-of-Care Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessCloudLeeds MoD spinout secures £200k for infection detection techLeeds startup Presymptom Health secured £200,000 in grant funding to accelerate its AI-driven infection detection technology. The cash will make its tests compatible with widely used PCR machines, including QuantuMDx and BMS platforms. The company plans a Series A round to expand into the US market.BusinessCloudLeeds MoD spinout secures £200k for infection detection techPresymptom Health, a Leeds spinout, secured £200k in grant funding to accelerate its AI-driven infection detection technology. The cash will make its tests compatible with multiple PCR machines, including QuantuMDx and BMS platforms. The company plans a Series A round to expand into the US market.BusinessCloudLeeds MoD spinout secures £200k for infection detection techPresymptom Health, a Leeds spinout, secured £200k in grant funding to accelerate its AI-driven infection detection technology. The cash will make its tests compatible with multiple PCR platforms, including QuantuMDx and BMS, for NHS adoption. The company plans a Series A round to expand into the US market.GlobeNewswireQuantuMDx receives CDTA approval for sale of Q-POC™ SARS-CoV-2, Flu A/B & RSV AssayQuantuMDx received CDTA approval for its Q-POC SARS-CoV-2, Flu A/B & RSV assay for sale in the UK. The multiplex respiratory panel is the first on the Q-POC device, with plans to add a sexually transmitted infections assay.PR NewswireQuantuMDx et Menarini annoncent un accord de distribution exclusive pour la plateforme Q-POC™QuantuMDx Group Limited and A.Menarini Diagnostics S.r.I. announced an exclusive distribution agreement for QuantuMDx's Q-POC™ platform in the United Kingdom and France. Menarini will handle the commercialization, sales, and after-sales service of the Q-POC™ and related tests, marking a significant business step for QuantuMDx. The initial agreement covers the UK and France, with potential expansion to other European countries and worldwide.PR NewswireQuantuMDx y Menarini anuncian un acuerdo de distribución exclusivo para la plataforma Q-POC™QuantuMDx Group Limited and A.Menarini Diagnostics have announced an exclusive five-year distribution agreement for QuantuMDx's Q-POC™ molecular diagnostic platform in the United Kingdom and France. Under this partnership, Menarini will handle the commercialization, sales, and service of the platform, which includes tests for SARS-CoV-2 and other respiratory viruses. The agreement includes provisions for potential expansion into other European and global markets.PR NewswireQuantuMDx und Menarini geben exklusive Vertriebsvereinbarung für die Q-POC™ Plattform bekanntQuantuMDx Group Limited, a UK-based molecular diagnostics developer, and A.Menarini Diagnostics S.r.I. have announced an exclusive five-year distribution agreement for the Q-POC™ testing platform in the United Kingdom and France. Menarini will market, sell, and support Q-POC™ along with its SARS-CoV-2 test and the new SARS-CoV-2, Flu A/B, and RSV Respiratory Panel. The agreement includes an option to expand to other European markets and globally, which QuantuMDx states will accelerate commercial distribution of its point-of-need molecular diagnostics platform.PR NewswireQuantuMDx e Menarini annunciano un Accordo di Distribuzione Esclusiva per la Piattaforma Q-POC™QuantuMDx Group Limited and A. Menarini Diagnostics S.r.I. have signed an exclusive five-year distribution agreement for QuantuMDx's Q-POC™ molecular diagnostics platform in the United Kingdom and France. Under this partnership, Menarini will handle the commercialization, sales, and technical support of the Q-POC™ device along with its associated respiratory and SARS-CoV-2 test panels. The agreement includes provisions for potential expansion into other European and global markets.PR NewswireQuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ PlatformQuantuMDx Group Limited, a UK-based molecular diagnostics developer, and A.Menarini Diagnostics S.r.I. have entered an exclusive five-year distribution agreement for the Q-POC™ diagnostics platform covering the UK and France, with potential for further market expansion. Menarini will handle marketing, sales, and servicing of the Q-POC™ system and its diagnostic tests including SARS-CoV-2 and respiratory panel assays. The partnership aims to accelerate commercial sales and expand access to rapid molecular diagnostics across clinical and non-clinical settings in new markets.GlobeNewswireQuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ PlatformQuantuMDx and Menarini announced an exclusive distribution agreement for the Q-POC platform in the UK and France, with potential to expand to other European and worldwide markets. The five-year deal covers Menarini's marketing, sales, and servicing of the SARS-CoV-2 assay and new respiratory panel. QuantuMDx plans to launch additional syndromic multiplex testing assays over the coming months and years.